Skip to main content
All lobbying filings

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA filed a Q1 report for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA on April 20, 2026.

Lobbying for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

All filings by PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Everything PROFESSIONAL COMPOUNDING CENTERS OF AMERICA has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$220,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Texas

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Pharmacy

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act

Medicare/Medicaid

Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees

Budget/Appropriations

Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem